Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 19, 2017
Impax Announces Sale of Taiwan Manufacturing Facility
Dec 19, 2017
Amneal Brings Generic for Renvela® to Market
PDF format download (opens in new window)
Dec 18, 2017
Robert Stewart to Join Amneal Pharmaceuticals as President
Dec 11, 2017
Only Generic for Kenalog-40 Injection Approved: Available through Amneal Biosciences
PDF format download (opens in new window)
Dec 08, 2017
Impax Receives Tentative FDA Approval of Generic Coreg CR® (Carvedilol Phosphate) Extended-Release Capsules
Nov 28, 2017
Amneal Biosciences Introduces Generic Clolar®
PDF format download (opens in new window)
Nov 09, 2017
Impax Reports Third Quarter 2017 Results
Nov 08, 2017
Impax Laboratories Mourns the Passing of Board Member Richard A. Bierly
Nov 06, 2017
Impax Announces Successful Completion of Consent Solicitation with Respect to its 2.00% Convertible Senior Notes due 2022
Oct 30, 2017
Impax Announces Consent Solicitation
Oct 24, 2017
Amneal wins Leader of the Year & Company of the Year, Americas Awards
PDF format download (opens in new window)
Oct 23, 2017
Impax Announces FDA Approval and Launch of Generic Renvela® (Sevelamer Carbonate) Tablets, 800 mg
Oct 17, 2017
Amneal And Impax To Combine
Oct 03, 2017
Impax to Report Third Quarter 2017 Results on November 9, 2017
Sep 28, 2017
Amneal Generic for Minastrin® 24 Fe Now Available
PDF format download (opens in new window)
Sep 19, 2017
Impax to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 05, 2017
Impax to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Aug 14, 2017
Amneal Pharmaceuticals Issues Voluntary Nationwide Recall of Lorazepam Oral Concentrate, USP 2mg/mL, Due to Misprinted Dosing Droppers Supplied with the Product
PDF format download (opens in new window)
Aug 09, 2017
Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million
Aug 07, 2017
Amneal Oseltamivir Capsules, Generic for Tamiflu®, Now Available
PDF format download (opens in new window)
Aug 07, 2017
Impax Announces Settlement of Contract Litigation on Opana® ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets
Jul 17, 2017
Impax Announces FDA Approval of its AB Rated Generic Concerta® (Methylphenidate Hydrochloride) Extended-Release Tablets CII
Jul 05, 2017
Impax Announces FDA Approval and Launch of Additional Strengths of Generic Focalin XR® (Dexmethylphenidate Hydrochloride) Extended-Release Capsules CII
Jun 29, 2017
Impax to Report Second Quarter 2017 Results on August 9, 2017
Jun 15, 2017
Amneal Introduces Ezetimibe Tablets, New Generic for Zetia®
PDF format download (opens in new window)
Jun 08, 2017
Impax to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
May 17, 2017
Impax to Present at the UBS Global Healthcare Conference
May 11, 2017
Impax to Present at the Bank of America Merrill Lynch Healthcare Conference
May 10, 2017
Impax Reports First Quarter 2017 Financial Results
Apr 27, 2017
First FDA-Approved 100 mg Thiotepa Now Available through Amneal Biosciences as TEPADINA® (thiotepa) for Injection
PDF format download (opens in new window)
Apr 26, 2017
Impax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tablets)
Apr 21, 2017
Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmitriptan) Nasal Spray and Investigational Drug IPX203 at the 2017 American Academy of Neurology® Annual Meeting
Apr 11, 2017
Amneal Introduces Its First Nasal Spray: Generic Nasonex®
PDF format download (opens in new window)
Apr 06, 2017
Impax to Report First Quarter 2017 Results on May 10, 2017
Mar 30, 2017
Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
Mar 28, 2017
Amneal Biosciences Announces Launch of Levoleucovorin for Injection
PDF format download (opens in new window)
Mar 27, 2017
Impax Board of Directors Appoints Paul M. Bisaro President and CEO
Mar 01, 2017
Impax Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 27, 2017
Impax to Present at Upcoming Investor Conferences
Jan 31, 2017
Amneal Biosciences Introduces Third Institutional Product
PDF format download (opens in new window)
Jan 30, 2017
Amneal Introduces Alosetron Hydrochloride Tablets, New Generic for Lotronex®
PDF format download (opens in new window)
Jan 25, 2017
Impax to Report Fourth Quarter and Full Year 2016 Results on March 1, 2017
Jan 06, 2017
Impax Confirms Patent Challenge Relating to Generic Aubagio® (teriflunomide) Tablets, 14 mg
Jan 04, 2017
Impax to Present at 35th Annual J.P. Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top